Topic

Articles

The European Commission has approved an additional indication for Roche’s Tecentriq (atezolizumab) as a first-line monotherapy treatment for metastatic non-small cell lung cancer.

EC Approves Additional Indication for Roche’s Tecentriq in Lung Cancer Treatment

The collaboration will focus on up to three types of lung and gastrointestinal cancers.

Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

FDA approval rate speeds up despite COVID-19 complications.

FDA Ends 2020 with High Drug Approval Rate

The EC’s approval was based on positive results from a Phase III clinical trial that demonstrated a statistically significant and clinically meaningful improvement in patients compared to chemotherapy.

EC Approves Bristol Myers Squibb’s Opdivo in Second-Line Treatment of Esophageal Cancer

FDA has approved Evrysdi (risdiplam) for treating spinal muscular atrophy in adults and children.

FDA Approves Roche’s Spinal Muscular Atrophy Drug 

Roche has received approval from the European Commission for Rozlytrek (entrectinib), its newest anti-cancer drug, for two indications.

EC Approves Roche’s Newest Anti-Cancer Drug 

The companies have entered into an exclusive licensing agreement to develop, manufacture, and commercialize efinopegdutide, an investigational drug for treating nonalcoholic steatohepatitis.

Merck, Hanmi Pharmaceutical Partner in $870-Million Deal to Develop Liver Disease Drug

Innovate UK has awarded Epsilogen with further grant funding for the development of the next generation antibody treatments for ovarian cancer.

Innovate UK Awards Epsilogen Further Funding for Ovarian Cancer Treatments

VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.


VAR2 Pharmaceuticals Wins MilliporeSigma’s Advance Biotech Grant

Phesgo is a fixed-dose-combination subcutaneous injection of Perjeta (pertuzumab) and Herceptin (trastuzumab) for treating HER2-positive breast cancer.

Therapeutic-Specific Areas